FES - FES proto-oncogene, tyrosine kinase Gene

Homo sapiens

Also known as FPS

Gene ID: 2242 | Gene type: protein coding

About FES

Cytogenetic location: 15q26.1 Genomic coordinates (GRCh38): 15:90,884,504-90,895,776 (from NCBI)

This gene has 17 transcripts (splice variants), 193 orthologues, 32 paralogues and is associated with 56 phenotypes. Broad expression in spleen (RPKM 39.1), bone marrow (RPKM 25.6) and 23 other tissues.

Summary

This gene encodes the human cellular counterpart of a feline sarcoma retrovirus protein with transforming capabilities. The gene product has tyrosine-specific protein kinase activity and that activity is required for maintenance of cellular transformation. Its chromosomal location has linked it to a specific translocation event identified in patients with acute promyelocytic leukemia but it is also involved in normal hematopoiesis as well as growth factor and cytokine receptor signaling. Alternative splicing results in multiple variants encoding different isoforms.[provided by RefSeq, Jan 2009]

FES Products(4)

mRNA	Protein	Name
NM_001143783.1	NP_001137255.1	tyrosine-protein kinase Fes/Fps isoform 2
NM_001143784.1	NP_001137256.1	tyrosine-protein kinase Fes/Fps isoform 3
NM_001143785.2	NP_001137257.1	tyrosine-protein kinase Fes/Fps isoform 4
NM_002005.4	NP_001996.1	tyrosine-protein kinase Fes/Fps isoform 1

FES Protein Structure

FCH

SH2

Pkinase_Tyr

0
200
400
600
822 a.a.

Protein Preferred Names

Protein Names

tyrosine-protein kinase Fes/Fps

Oncogene FES, feline sarcoma virus

Recombinant FES Proteins

Cat. No.	Product Name	Accession	Purity
HY-P73050	FES Protein, Human (sf9, His-GST)	P07332-1 (M1-R822)	≥95%

Related Diseases

Diseases

Alias

Sarcoma

Connective And Soft Tissue Neoplasm	Tumor Of Soft Tissue And Skeleton
Sarcomas	Sarcoma - Category

Myeloid Leukemia

Myeloid Leukaemia	Leukaemia Myelogenous
Leukemia Myelogenous	Myeloid Granulocytic Leukaemia
Myeloid Granulocytic Leukemia	Non-Lymphocytic Leukemia
Leukemia, Myeloid	Granulocytic Leukaemia
Myelogenous Leukaemia	Myeloid Leukaemia, Unspecified, Without Mention Of Remission

Leukemia

Leukemias	Leukaemia, Unspecified, Without Mention Of Remission
Aleukemic Leukaemia	Chronic Leukaemia
Subacute Leukaemia	Leukaemia Disorder
Leukaemia Nos

Acute Promyelocytic Leukemia

Leukemia, Acute Promyelocytic	Acute Myeloblastic Leukemia Type 3
Aml M3	APL
Leukemia, Acute Promyelocytic, Somatic	Aml With T(15
17)(Q22	Q12)
(Pml/Raralpha) And Variants	Apml
Acute Myeloblastic Leukemia 3	Acute Myeloid Leukemia With T(15
17)(Q22	Q12)
(Pml/Raralpha) And Variants	Acute Myeloblastic Leukaemia Type 3
Acute Myeloid Leukaemia M3	Acute Myeloid Leukemia M3
Acute Promyelocytic Leukaemia	M3 Anll
Myeloid Leukemia, Acute, M3	Leukemia Promyelocytic Acute
Leukemia, Promyelocytic, Acute	Leukemia, Acute, Promyelocytic

Ewing Sarcoma Of Bone

Ewing'S Sarcoma Of Bone	Bone Ewing Sarcoma
Bone Ewing'S Sarcoma	Bone Localized Ewing Sarcoma
Bone Localized Ewing'S Sarcoma	Ewing'S Sarcoma/Bone Peripheral Primitive Neuroectodermal Tumor
Localized Skeletal Ewing'S Sarcoma	Localized Bone Ewing Sarcoma

Myopathy, Centronuclear, 2

Myopathy, Centronuclear, Autosomal Recessive	Autosomal Recessive Centronuclear Myopathy
CNM2	Centronuclear Myopathy 2
Ar-Cnm	Myotubular Myopathy, Autosomal Recessive
Autosomal Recessive Myotubular Myopathy	Centronuclear Myopathy Autosomal Recessive
Myopathy, Centronuclear, Type 2

Melanoma

Malignant Melanoma	Cutaneous Melanoma
Naevocarcinoma	Malignant Melanomas

Leukemia, Chronic Myeloid

Chronic Myeloid Leukemia	Chronic Myelogenous Leukemia
CML	Chronic Granulocytic Leukemia
Leukemia, Philadelphia Chromosome-Positive, Resistant To Imatinib	Chronic Myeloid Leukaemia
Chronic Granulocytic Leukaemia	Chronic Myelogenous Leukaemia
Myeloid Leukemia, Chronic	Leukemia, Chronic Myelogenous
Leukemia, Chronic Myeloid, Philadelphia Chromosome Positive, Somatic	Cml - Chronic Myelogenous Leukemia
Cgl	Chronic Myelocytic Leukemia
Leukemia, Chronic Myeloid, Atypical	ACML
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative	Myeloid Leukemia Chronic
Leukemia, Myeloid, Chronic	Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative
Cml- [Chronic Myeloid Leukaemia]	Cgl - [Chronic Granulocytic Leukaemia]
Chronic Myelocytic Leukaemia

Prostate Cancer

Prostate Carcinoma	Prostate Cancer, Familial
Prostate Neoplasm	Prostate Cancer, Somatic
Prostate Cancer, Susceptibility To	Prostatic Cancer
Prostatic Neoplasms	Hereditary Prostate Cancer
Prostatic Neoplasm	Cancer Of Prostate
Carcinoma Of Prostate	Familial Prostate Cancer
Familial Prostate Carcinoma	Malignant Tumor Of Prostate
Malignant Neoplasm Of Prostate	Prostate Cancer, Familial, Susceptibility To
Malignant Tumor Of The Prostate	Ngp - New Growth Of Prostate
Tumor Of The Prostate	Prostate Cancer, Hereditary
Cancer Of The Prostate	Malignant Neoplasm Of The Prostate
Prostatic Carcinoma	PC
Prca	Cancer, Prostate
Malignant Prostatic Tumour	Malignant Tumour Of Prostate
Primary Prostate Cancer	Primary Malignant Neoplasm Of Prostate
Prostate Gland Cancer

Diseases	Alias
Waldenstroem'S Macroglobulinemia	Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma Waldenstroem'S Macroglobulinemia Waldenstroem'S Macroglobulinemia Macroglobulinemia Of Waldenstrom Lymphoplasmacytic Lymphoma With Igm Gammopathy Lymphoplasmacytic Lymphoma

Related Agents

Approval

Bioactive Molecules (5)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-B0988	Deferoxamine mesylate		99.86%	Yes
HY-B1625	Deferoxamine		≥98.0%	Yes
HY-107928	Iron dextran		/	Unkown
HY-108017	Ferric maltol		99.93%	Yes
HY-16564	Deferasirox (Fe3+ chelate)	Inhibitor	≥98.0%	Unkown

Clinical Phase

Bioactive Molecules (9)

Cat. No.	Product Name	Effect	Purity	Phase
HY-12040	Elesclomol		99.80%	Phase 3
HY-17609	Difelikefalin	Agonist	99.50%	Phase 3
HY-114758	Pyridoxal isonicotinoyl hydrazone		98.28%	Phase 3
HY-P1714	Apraglutide		99.37%	Phase 3
HY-105239A	Selepressin acetate	Agonist	98.77%	Phase 3
HY-P1714A	Apraglutide TFA		98.01%	Phase 3
HY-105239	Selepressin	Agonist	/	Phase 3
HY-122844	Ifebemtinib	Inhibitor	99.86%	Phase 2
HY-P3516	Barusiban	Antagonist	/	Phase 2

Pre-clinical Phase

Bioactive Molecules (33)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-D1533	RhoNox-1		98.54%	Unkown
HY-W004544	o-Phenanthroline	Inhibitor	99.88%	Unkown
HY-126823	Phen Green SK diacetate (5/6-mixture)		95.33%	Unkown
HY-137805	Ferrozine		99.96%	Unkown
HY-N0928	Mimosine		99.92%	Unkown
HY-Y1841	o-Phenanthroline monohydrate	Inhibitor	99.38%	Unkown
HY-W075707	FeTCPP		≥95.0%	Unkown
HY-N10473	Pulcherriminic acid	Inhibitor	≥98.0%	Unkown
HY-D0945	Xylene Cyanol FF		97.46%	Unkown
HY-156776	HAPSBC		≥95.0%	Unkown
HY-P3267A	Apo-Transferrin	Activator	≥95.0%	Unkown
HY-145157	Ferric nitrilotriacetate		/	Unkown
HY-N0046	Notoginsenoside Fe		99.98%	Unkown
HY-136300	PHD-1-IN-1	Inhibitor	99.73%	Unkown
HY-107928A	Iron–Dextran(Fe 25-35% w/w)		/	Unkown
HY-107928B	Iron–Dextran(Fe 35-40% w/w)		/	Unkown
HY-115832	Ap44mSe		/	Unkown
HY-143249	MtMetAP1-IN-1	Inhibitor	/	Unkown
HY-145286	IMPDH2-IN-2		/	Unkown
HY-149418	BChE/HDAC6-IN-2	Inhibitor	/	Unkown
HY-155158	Anticancer agent 147	Inducer	/	Unkown
HY-157917	Nitro-PAPS disodium dihydrate		/	Unkown
HY-160414	TRX-COBI	Inhibitor	/	Unkown
HY-B1159S	Nitroxoline-D4		/	Unkown
HY-D2204	SHP1-IN-1	Inhibitor	/	Unkown
HY-RS04867	FES Human Pre-designed siRNA Set A		/	Unkown
HY-W004544S	o-Phenanthroline-d8	Inhibitor	/	Unkown
HY-W011816	1,2-Hexadecanediol		/	Unkown
HY-W112939	Fe(III)(TDCPP) chloride		/	Unkown
HY-W686216	VK-28		/	Unkown
HY-148340	24RBPyBC		/	Unkown
HY-W112021	2,5-DMBQ		/	Unkown
HY-100332	CP 375		/	Unkown

Orthologs Information

Species	Symbol	Source	ID
Mus musculus	FES	MGD	MGI:95514
Bos taurus	FES	VGNC	VGNC:28954
Macaca mulatta	FES	VGNC	VGNC:72637
Rattus norvegicus	FES	RGD	RGD:1564385
Felis catus	FES	VGNC	VGNC:62232
Canis familiaris	FES	VGNC	VGNC:40825
Others	FES	NCBI

Name
Email *

	Sorry, but the email address you supplied was invalid.